|
US6787532B2
(en)
|
2000-08-05 |
2004-09-07 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivatives
|
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
AU2001276497B2
(en)
|
2000-08-05 |
2005-04-07 |
Glaxo Group Limited |
17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
|
|
GB0019172D0
(en)
|
2000-08-05 |
2000-09-27 |
Glaxo Group Ltd |
Novel compounds
|
|
US6750210B2
(en)
|
2000-08-05 |
2004-06-15 |
Smithkline Beecham Corporation |
Formulation containing novel anti-inflammatory androstane derivative
|
|
US6858596B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivative
|
|
US6777399B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
US6858593B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
|
GB0103630D0
(en)
|
2001-02-14 |
2001-03-28 |
Glaxo Group Ltd |
Chemical compounds
|
|
UA77656C2
(en)
|
2001-04-07 |
2007-01-15 |
Glaxo Group Ltd |
S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
|
|
ATE411334T1
(de)
|
2001-04-30 |
2008-10-15 |
Glaxo Group Ltd |
Antiphlogistische 7.beta.-carbothioate esterderivate von androstan mit einer 17.alpha.- zyklischen estergruppe
|
|
CN101701006B
(zh)
|
2001-09-14 |
2014-03-05 |
葛兰素集团有限公司 |
治疗呼吸疾病的苯乙醇胺衍生物
|
|
JP2005507881A
(ja)
|
2001-09-17 |
2005-03-24 |
グラクソ グループ リミテッド |
乾燥粉末医薬製剤
|
|
US20030229058A1
(en)
|
2001-11-13 |
2003-12-11 |
Moran Edmund J. |
Aryl aniline beta2 adrenergic receptor agonists
|
|
TWI249515B
(en)
|
2001-11-13 |
2006-02-21 |
Theravance Inc |
Aryl aniline beta2 adrenergic receptor agonists
|
|
AU2003205855A1
(en)
*
|
2002-02-04 |
2003-09-02 |
Glaxo Group Limited |
Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
|
|
US6747043B2
(en)
|
2002-05-28 |
2004-06-08 |
Theravance, Inc. |
Alkoxy aryl β2 adrenergic receptor agonists
|
|
GB2389530B
(en)
|
2002-06-14 |
2007-01-10 |
Cipla Ltd |
Pharmaceutical compositions
|
|
EP1554264B1
(en)
*
|
2002-10-22 |
2007-08-08 |
Glaxo Group Limited |
Medicinal arylethanolamine compounds
|
|
GB0225540D0
(en)
*
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Medicinal compounds
|
|
GB0303396D0
(en)
|
2003-02-14 |
2003-03-19 |
Glaxo Group Ltd |
Medicinal compounds
|
|
PE20040950A1
(es)
|
2003-02-14 |
2005-01-01 |
Theravance Inc |
DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
|
|
WO2004101525A1
(en)
|
2003-05-08 |
2004-11-25 |
Theravance, Inc. |
Crystalline form of aryl aniline beta-2 adrenergic receptor agonist
|
|
TW200510277A
(en)
|
2003-05-27 |
2005-03-16 |
Theravance Inc |
Crystalline form of β2-adrenergic receptor agonist
|
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
|
TW200526547A
(en)
*
|
2003-09-22 |
2005-08-16 |
Theravance Inc |
Amino-substituted ethylamino β2 adrenergic receptor agonists
|
|
DE102004001413A1
(de)
*
|
2004-01-09 |
2005-08-18 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung
|
|
TW200531692A
(en)
*
|
2004-01-12 |
2005-10-01 |
Theravance Inc |
Aryl aniline derivatives as β2 adrenergic receptor agonists
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
TWI341836B
(en)
|
2004-03-11 |
2011-05-11 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
AR049384A1
(es)
|
2004-05-24 |
2006-07-26 |
Glaxo Group Ltd |
Derivados de purina
|
|
RU2006146042A
(ru)
*
|
2004-06-03 |
2008-07-20 |
Тереванс |
Диаминные агонисты 2-адренергических рецепторов
|
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
|
US7317023B2
(en)
*
|
2004-07-21 |
2008-01-08 |
Theravance, Inc. |
Diaryl ether β2 adrenergic receptor agonists
|
|
GB0418045D0
(en)
|
2004-08-12 |
2004-09-15 |
Glaxo Group Ltd |
Compounds
|
|
JP2008510014A
(ja)
|
2004-08-16 |
2008-04-03 |
セラヴァンス, インコーポレーテッド |
β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
|
|
WO2006023460A2
(en)
|
2004-08-16 |
2006-03-02 |
Theravance, Inc. |
COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
|
|
EP1786762A2
(en)
*
|
2004-09-10 |
2007-05-23 |
Theravance, Inc. |
Amidine substituted aryl aniline compounds
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
EP1841780B1
(en)
|
2005-01-10 |
2011-07-27 |
Glaxo Group Limited |
Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
|
|
TWI389690B
(zh)
|
2005-03-25 |
2013-03-21 |
Glaxo Group Ltd |
新穎化合物(一)
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
ES2265276B1
(es)
|
2005-05-20 |
2008-02-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
|
BRPI0614290A2
(pt)
|
2005-08-08 |
2011-03-22 |
Argenta Discovery Ltd |
derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
|
|
PT2532679T
(pt)
|
2005-10-21 |
2017-07-18 |
Novartis Ag |
Anticorpos humanos contra il13 e utilizações terapêuticas
|
|
AR058109A1
(es)
|
2005-12-20 |
2008-01-23 |
Glaxo Group Ltd |
Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
AU2007242851A1
(en)
|
2006-04-20 |
2007-11-01 |
Glaxo Group Limited |
Novel compounds
|
|
SI2013211T1
(sl)
|
2006-04-21 |
2012-07-31 |
Novartis Ag |
Purinski derivati za uporabo kot agonisti receptorja adenozina A A
|
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
|
CL2007001829A1
(es)
|
2006-06-23 |
2008-01-25 |
Smithkline Beecham Corp |
P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
|
|
WO2008015416A1
(en)
|
2006-08-01 |
2008-02-07 |
Glaxo Group Limited |
Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
|
|
HRP20110201T1
(hr)
|
2007-01-10 |
2011-08-31 |
Irm Llc |
Spojevi i sastavi kao inhibitori proteaze kanalizirane aktivacije
|
|
WO2008097673A1
(en)
|
2007-02-09 |
2008-08-14 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
|
AR065804A1
(es)
|
2007-03-23 |
2009-07-01 |
Smithkline Beecham Corp |
Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
|
|
EP2332933A1
(en)
|
2007-05-07 |
2011-06-15 |
Novartis AG |
Epithelial sodium channel (ENaC) inhibitors
|
|
ES2320961B1
(es)
|
2007-11-28 |
2010-03-17 |
Laboratorios Almirall, S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
|
|
AR069637A1
(es)
|
2007-12-10 |
2010-02-10 |
Novartis Ag |
Derivados de pirazinas
|
|
MX2010007604A
(es)
|
2008-01-11 |
2010-08-02 |
Novartis Ag |
Pirimidinas como inhibidores de cinasa.
|
|
WO2010068311A1
(en)
|
2008-05-23 |
2010-06-17 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein inhibitor
|
|
JP5502858B2
(ja)
|
2008-06-05 |
2014-05-28 |
グラクソ グループ リミテッド |
Pi3キナーゼの阻害剤として有用な4−カルボキサミドインダゾール誘導体
|
|
BRPI0915018A2
(pt)
|
2008-06-10 |
2015-10-27 |
Novartis Ag |
compostos orgânicos
|
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
|
NZ594157A
(en)
|
2008-12-30 |
2013-07-26 |
Pulmagen Therapeutics Inflammation Ltd |
Sulfonamide compounds for the treatment of respiratory disorders
|
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
|
JP5656880B2
(ja)
|
2009-03-09 |
2015-01-21 |
グラクソ グループ リミテッドGlaxo Group Limited |
Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール
|
|
WO2010102968A1
(en)
|
2009-03-10 |
2010-09-16 |
Glaxo Group Limited |
Indole derivatives as ikk2 inhibitors
|
|
EP2228368A1
(en)
|
2009-03-12 |
2010-09-15 |
Almirall, S.A. |
Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
|
|
WO2010106016A1
(en)
|
2009-03-17 |
2010-09-23 |
Glaxo Group Limited |
Pyrimidine derivatives used as itk inhibitors
|
|
US20120035247A1
(en)
|
2009-03-19 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
EA201171144A1
(ru)
|
2009-03-19 |
2012-04-30 |
Мерк Шарп Энд Домэ Корп. |
ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
|
US20120029054A1
(en)
|
2009-03-19 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
|
|
WO2010107952A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
WO2010111464A1
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
WO2010111468A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
|
AU2010229847A1
(en)
|
2009-03-27 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA)
|
|
EP2411520A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
JP2012524754A
(ja)
|
2009-04-24 |
2012-10-18 |
グラクソ グループ リミテッド |
Cracチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
|
|
EP2421835A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
N-pyrazolyl carboxamides as crac channel inhibitors
|
|
PT2899191T
(pt)
|
2009-04-30 |
2017-11-14 |
Glaxo Group Ltd |
Indazoles substituídos com oxazole como inibidores de pi3-cinase
|
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
|
HRP20151344T1
(hr)
|
2009-07-15 |
2016-01-01 |
Theravance Biopharma R&D Ip, Llc |
Kristalni oblik slobodne baze bifenilnog spoja
|
|
JP2013508414A
(ja)
|
2009-10-22 |
2013-03-07 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
嚢胞性線維症および他の慢性疾患の治療のための組成物
|
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
|
WO2011067364A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Novel compounds
|
|
JP2013512880A
(ja)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
Pi3−キナーゼ阻害剤としてのインダゾール誘導体
|
|
JP2013512879A
(ja)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体
|
|
EP2512438B1
(en)
|
2009-12-16 |
2017-01-25 |
3M Innovative Properties Company |
Formulations and methods for controlling mdi particle size delivery
|
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
|
SI2614058T1
(sl)
|
2010-09-08 |
2015-10-30 |
Glaxosmithkline Intellectual Property Development Limited |
Polimorfi in soli N-(5-(4-(5-(((2R,6S)-2,6-dimetil-4-morfolinil)metil)-1,3-oksazol-2-il)- 1H-indazol-6-il)-2-(metiloksi)-3-piridinil)metansulfonamida
|
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
JP5795643B2
(ja)
|
2010-10-21 |
2015-10-14 |
グラクソ グループ リミテッドGlaxo Group Limited |
アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
|
|
EP2630127A1
(en)
|
2010-10-21 |
2013-08-28 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
|
MX2013009767A
(es)
|
2011-02-25 |
2013-10-01 |
Irm Llc |
Compuestos y composiciones como inhibidores de trk.
|
|
US20140005188A1
(en)
|
2011-03-11 |
2014-01-02 |
Glaxo Group Limited |
Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
|
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
|
UY34305A
(es)
|
2011-09-01 |
2013-04-30 |
Novartis Ag |
Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
US9056867B2
(en)
|
2011-09-16 |
2015-06-16 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
|
ES2558457T3
(es)
|
2011-09-16 |
2016-02-04 |
Novartis Ag |
Compuestos heterocíclicos para el tratamiento de fibrosis quística
|
|
EP2578570A1
(en)
|
2011-10-07 |
2013-04-10 |
Almirall, S.A. |
Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
EP2641900A1
(en)
|
2012-03-20 |
2013-09-25 |
Almirall, S.A. |
Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
CA2902400C
(en)
|
2013-03-15 |
2021-05-04 |
Verona Pharma Plc |
Pde3/4 inhibitor/.beta.2-adrenergic agonist combination
|
|
CN105658218A
(zh)
|
2013-10-17 |
2016-06-08 |
葛兰素史克知识产权开发有限公司 |
用于治疗呼吸疾病的pi3k抑制剂
|
|
CN105611929A
(zh)
|
2013-10-17 |
2016-05-25 |
葛兰素史克知识产权开发有限公司 |
用于治疗呼吸系统疾病的pi3k抑制剂
|
|
US9862711B2
(en)
|
2014-04-24 |
2018-01-09 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
WO2015162459A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
US10112926B2
(en)
|
2014-04-24 |
2018-10-30 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
AU2015260841A1
(en)
|
2014-05-12 |
2016-12-01 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pharmaceutical compositions comprising danirixin for treating infectious diseases
|
|
GB201602527D0
(en)
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
JP2019524792A
(ja)
|
2016-08-08 |
2019-09-05 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
化合物
|
|
GB201706102D0
(en)
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
GB201712081D0
(en)
|
2017-07-27 |
2017-09-13 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
AU2020290094B2
(en)
|
2019-06-10 |
2024-01-18 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
|
|
KR20220052934A
(ko)
|
2019-08-28 |
2022-04-28 |
노파르티스 아게 |
치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
|
|
CN110698356A
(zh)
*
|
2019-11-07 |
2020-01-17 |
南京恒远科技开发有限公司 |
N-苄基甘氨酸乙酯的制备及纯化方法
|
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|
|
CN114057712A
(zh)
*
|
2021-12-03 |
2022-02-18 |
广东莱佛士制药技术有限公司 |
一种合成手性苯基噁唑烷-2-酮的方法
|